MOPDA 0205: Models for Mucosal Immunity and Transmission

1
MOPDA 02-05 Models for Mucosal Immunity and
Transmission

• Host Parasite Relationship. Human-HIV
  Relationship, What happens on the site?
• Four papers cover
• 1)Innate mucosal immunity to HIV(Hayes)CV
  explants,TLR ligands, Innate R5 HIV resistance,
  Soluble factor, Identification
• 2)Acquired mucosal immunity to HIV(Sarna)Sex
  worker cohort, Mucosal IgA, Cloning, Production
  in large quantity, antibody-based topical
  microbicides remains attractive endevour.
• 3)Dendrimer-based microbicides (Wasselingh)SPL701
  3 undergoing clinical evaluation, Attempt to
  isolate resistant HIV-1, Active against various
  isolates
• 4)New technology utilising PA-GFP labeled
  HIV(McCoombe) Human foreskin and CV explants,
  Rhesus model, Langerhans cells and CD4 T cells,
  Initial dynamism of HIV ON the SITE,

2
What happens on the SITE?
(Nakasone)
Artificial defense
HIV
(Microbicides, IgG, IgA, drugs etc)
Cell-assoc.virus
Free virus
?
Glycan-related enzymes Proteases
Provirus ?
?
Mucin (Langerin, etc)
Accelerate or decelerate?
Host
?
pH
Natural defense
Mucosa
3
To develop effective Vaccines and Microbicides

• Which cells are the first to interact with HIV?
• Which cells are to be productively infected with
  the virus?
• What kind of environmental factors are involved
  that affect infection?
• Are there any local immune responses against the
  virus?
• Sterilizing Immunity

Pope and Haase, Nature Med.2003
4
Vaccine protection to HIV

• Requires approaches yielding persistent immune
  responses that are sustained at the time as well
  as on the site of HIV exposure and to provide
  durable protection against AIDS

DC,FDC
T-cell
Mucosa